Greater Cannabis Company, Inc. logo

Greater Cannabis Company, Inc.

GCAN
Last price US$0.27
Market cap US$292.9m
12M price change -9.97%
Loading the 12-month Mave Thesis and 1-month news signal

Dashboard Funda..tals Prediction Screener Map

Greater Cannabis Company, Inc. Overview

Industry: Drug Manufacturers Specialty & Generic

Sector: Healthcare

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company was founded in 2014 and is based in Baltimore, Maryland. The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company was founded in 2014 and is based in Baltimore, Maryla Read More

Mavefund brings filings, fundamentals, valuation, price history and news for Greater Cannabis Company, Inc. into one research view. The sections below show what strengthens or weakens the research case.

Score

Reported Results

What the company reported, with filing details kept small.

Filed May 13, 2026

Quarterly result summary

Latest company-filed earnings material is available for source review.

What changed

  • Review the SEC source filing for the full reported results and management commentary.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

SEC filing Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

No qualified company news in the last 14 days

No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

Earnings Per Share

Score 2.00/5
Greater Cannabis Company, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Return on Equity

Score 1.83/5
Greater Cannabis Company, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Greater Cann... GCAN US$292.9m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Net Margin

Score 0.32/5
Greater Cannabis Company, Inc. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Greater Cann... GCAN US$292.9m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Share Buyback

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Leverage

Score 3.00/5
Greater Cannabis Company, Inc. attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Greater Cann... GCAN US$292.9m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Verified SEC statements load when this section enters view.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Greater Cannabis Company, Inc. logo

Greater Cannabis Company, Inc.

US$0.27

US$292.9m

-9.97%

-9.97%